A vaccine effective against human papillomaviruses (HPV), which are thought responsible for most cases of cervical and anal cancers, enters clinical trials in Japan this month. If the trial is successful, the vaccine would be the first used to prevent cancer, claim its developers, a group of researchers from the University of Tokyo and the National Institute of Infectious Diseases reports Japanese newspaper Yomiuri Shimbun. US-based researchers have already tested more than 10 vaccines against specific HPVs but the Japanese vaccine, which targets protein common to all HPVs, is expected to treat every strain.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.